Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
AuthorMcClure, T; Cui, W; Asadi, K; John, T; Testro, A
Source TitleBMJ Open Gastroenterology
University of Melbourne Author/sTestro, Adam
Document TypeJournal Article
CitationsMcClure, T., Cui, W., Asadi, K., John, T. & Testro, A. (2020). Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.. BMJ Open Gastroenterol, 7 (1), pp.e000487-e000487. https://doi.org/10.1136/bmjgast-2020-000487.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References